Combinations of different approaches such as WGS-based, FDA-approved assays, and newer functional assays such as the RAD51 foci assay (Pellegrino et al., 2022) will ultimately lead to a better selection of HRD patients for appropriate therapies. Here, RAD51 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.